Tumor Biology

, Volume 34, Issue 2, pp 983–986 | Cite as

Characterization of cell-free circulating DNA in plasma in patients with prostate cancer

  • Pâmela Oliveira Delgado
  • Beatriz Costa A. Alves
  • Flávia de Sousa Gehrke
  • Renata Kelly Kuniyoshi
  • Marcelo Langer Wroclavski
  • Auro Del Giglio
  • Fernando Luiz Affonso Fonseca
Research Article

Abstract

Cell-free circulating DNA in plasma and serum may serve as a biomarker for malignant tumor detection and follow up in patients with a variety of solid tumors including prostate cancer. In healthy patients, DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe. Cell-free circulating DNA levels were measured by a quantitative real-time PCR method with a set of primers targeted to amplify the consensus ALU apoptotic versus necrotic origin. Prostate cancer patients before and 3 months after diagnosis showed cell-free circulating DNA released at apoptotic and non-apoptotic cell death. Interestingly, all patients after 6 months demonstrated DNA released at non-apoptotic cell. The principal source of cell-free circulating DNA is of apoptotic and non-apoptotic cell death. However, during treatment, this feature could change. Therefore, the study of cell-free circulating DNA would be important to follow the evolution of the disease during the treatment.

Keywords

Prostate Cancer Cell-free circulating DNA DNA integrity ALU sequence 

References

  1. 1.
    Instituto Nacional de Câncer-INCA Tipos de Câncer–Próstata http://www2.inca.gov.br/wps/wcm/connect/tiposdecancer/site/home/prostata. Accessed 23 Oct 2012.
  2. 2.
    Canadian Cancer Society http://www.cancer.ca/. Accessed 23 Oct 2012.
  3. 3.
    Souto CAV, Fonseca GN, Carvalhal GF, Barata HS, Souto JCS, Berger M. Sociedade Brasileira de Urologia–Câncer de Próstata: Marcadores Tumorais. 2006 http://www.projetodiretrizes.org.br/5_volume/09-CancerMar.pdf. Accessed 23 Oct 2012.
  4. 4.
    Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–65.PubMedGoogle Scholar
  5. 5.
    Naoyuki U, Armando EG, Suzanne HH, Farin A, Taku N, Silvana M, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;26:4270–6.Google Scholar
  6. 6.
    Naoyuki U, Armando EG, Suzanne HH, Farin A, Taku N, Silvana M, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. 2006;52(6):1062–9Google Scholar
  7. 7.
    Sai S, Ichikawa D, Towita H, et al. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 2007;27:2747–52.PubMedGoogle Scholar
  8. 8.
    Swanson PE, Carroll SB, Zhang XF, Mackey MA. Spontaneus premature chromosome condensation, micronucleus formation, and non-apoptotic cell death in heated Hela S3 cell. Ultrastructural observations. Am J Pathol. 1995;146:963–71.PubMedGoogle Scholar
  9. 9.
    Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 2001;4:303–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, et al. Increased plasm DNA integrity in cancer patients. Cancer Res. 2003;63:3966–8.PubMedGoogle Scholar
  11. 11.
    Serpa Neto A, Wroclawski ML, Pinto JLF, Marsicano SR, Delgado PO, Coelho PG, et al. Methodological standardization for the extraction of free DNA in plasma of peripheral blood. J Cancer Sci Ther. 2012;1:1–5.CrossRefGoogle Scholar
  12. 12.
    Chan KCA, Leung S-F, Yeung S-W, Chan ATC, Lo YMD. Persistent aberrations in circulating DNA integrity after radiotherapy are associate with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res. 2008;14(13):4141–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, Wu X, Ju S, Chen J. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci. 2012;46:470–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Jiang W-W, Zahurak M, Goldenberg D, Milman Y, Park HL, Westra WH, Koch W, Sidransky D, Califano J. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer. 2006;119:2673–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Gao Y-J, He Y-J, Yang Z-L, Shao H-Y, Zuo Y, Bai Y, Chen H, Chen X-C, Qin F-X, Tan S, Wang J, Wang L, Zhang L. Increased integrity of circulating cell-free DNA in plasma of patients with acute leukemia. Clin Chem Lab Med. 2010;48(11):1651–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008;46(3):311–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Coelho PG, Marsicano SR, Delgado PO, Pinto JLF, Sant'Anna AVL, Yabiko MY, et al. Chemotherapy induces genomic instability in oral mucosal cells of women with breast cancer. J Solid Tumors. 2012;2:10–4.Google Scholar
  18. 18.
    Birch L, English CA, O’Donoghue K, Barigye O, Fisk NM, Keer JT. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem. 2005;21(2):320–1.Google Scholar
  19. 19.
    Ellinger J, Wittkamp V, Albers P, Perabo FGE, Mueller SC, von Ruecker A, Bastian PJ. Cell-free circulating DNA: diagnostic value in patients with testicular germ cell cancer. J Urol. 2009;181:363–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Jin Z, EI-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther. 2005;4:139–63.PubMedCrossRefGoogle Scholar
  21. 21.
    Allen D, Butt A, Cahill D, Wheeler M, Popert R, Swaminathan R. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer. Ann N Y Acad Sci. 2004;1022:76–80.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Pâmela Oliveira Delgado
    • 1
  • Beatriz Costa A. Alves
    • 1
  • Flávia de Sousa Gehrke
    • 1
  • Renata Kelly Kuniyoshi
    • 1
  • Marcelo Langer Wroclavski
    • 2
  • Auro Del Giglio
    • 1
  • Fernando Luiz Affonso Fonseca
    • 1
    • 3
  1. 1.Oncology/Hematology DisciplineFMABCSanto AndréBrazil
  2. 2.Urology DisciplineFMABCSanto AndréBrazil
  3. 3.Biological Science DepartmentUNIFESPDiademaBrazil

Personalised recommendations